Pharmacokinetic and pharmacodynamic properties of eptifibatide in subjects with normal or impaired renal functionGRETLER, Daniel D; GUERCIOLINI, Roberto; WILLIAMS, Paul J et al.Clinical therapeutics. 2004, Vol 26, Num 3, pp 390-398, issn 0149-2918, 9 p.Article

Glycoprotein IIb/IIIa inhibitors in patients with end-stage renal diseaseVILLENEUVE, Eric; SUNDERJI, Rubina.The Annals of pharmacotherapy. 2005, Vol 39, Num 4, pp 732-735, issn 1060-0280, 4 p.Article

Switch from abciximab to eptifibatide during percutaneous coronary interventionWAHLIN, Magnus; ALBERTSSON, Per; KARLSSON, Thomas et al.International journal of cardiology. 2009, Vol 134, Num 3, pp 393-400, issn 0167-5273, 8 p.Article

The state of platelets preserved in extracorporeal circulation with a glycoprotein IIb/IIIa inhibitorKONDO, Norihiro; WAKAYAMA, Fuminori; SUZUKI, Yasuyuki et al.Thrombosis research. 2004, Vol 113, Num 5, pp 303-310, issn 0049-3848, 8 p.Article

2012 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline and Replacing the 2011 Focused Update)JNEID, Hani; ANDERSON, Jeffrey L; GANIATS, Theodore G et al.Circulation (New York, N.Y.). 2012, Vol 126, Num 7, pp 875-910, issn 0009-7322, 36 p.Article

Pharmacokinetic and pharmacodynamic properties of eptifibatide in healthy subjects receiving unfractionated heparin or the low-molecular-weight heparin enoxaparinGRETLER, Daniel D.Clinical therapeutics. 2003, Vol 25, Num 10, pp 2564-2574, issn 0149-2918, 11 p.Article

Contemporary use of glycoprotein IIb/IIIa inhibitorsKRISTENSEN, Steen Dalby; WÜRTZ, Morten; GROVE, Erik Lerkevang et al.Thrombosis and haemostasis. 2012, Vol 107, Num 2, pp 215-224, issn 0340-6245, 10 p.Article

2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/ Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice GuidelinesCirculation (New York, N.Y.). 2011, Vol 123, Num 18, pp 2022-2060, issn 0009-7322, 39 p.Article

Use of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention: insights from the APEX-AMI trialHUBER, Kurt; HOLMES, David R; VAN 'T HOF, Arnoud W et al.European heart journal. 2010, Vol 31, Num 14, pp 1708-1716, issn 0195-668X, 9 p.Article

Clinical implications of the results of recent atherothrombotic trials on patient managementBETRIU, Amadeo.European heart journal supplements. 2008, Vol 10, Num I, issn 1520-765X, I30-I32Article

Upstream Use of Small-Molecule Glycoprotein IIb/IIIa Inhibitors in Patients With Non―ST-Segment Elevation Acute Coronary Syndromes: A Systematic Overview of Randomized Clinical TrialsTRICOCI, Pierluigi; KRISTIN NEWBY, L; ARMSTRONG, Paul W et al.Circulation. Cardiovascular quality and outcomes (Print). 2011, Vol 4, Num 4, pp 448-458, issn 1941-7713, 11 p.Article

Age, treatment, and outcomes in high-risk non-ST-segment elevation acute coronary syndrome patients: Insights from the EARLY ACS trialLOPES, Renato D; WHITE, Jennifer A; GIBSON, C. Michael et al.International journal of cardiology. 2013, Vol 167, Num 6, pp 2580-2587, issn 0167-5273, 8 p.Article

Pexelizumab may be hazardous to those with ST-segment elevation myocardial infarction undergoing primary percutaneous interventions without using glycoprotein IIb-IIIa inhibitorsLIN, Gen-Min; CHU, Kai-Min; HAN, Chih-Lu et al.International journal of cardiology. 2011, Vol 146, Num 2, pp 280-282, issn 0167-5273, 3 p.Article

Mortality at 1 year for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization : do tirofiban and ReoPro give similar efficacy outcomes at trial 1-year follow-upMUKHERJEE, Debabrata; TOPOL, Eric J; ARDISSINO, Diego et al.European heart journal. 2005, Vol 26, Num 23, pp 2524-2528, issn 0195-668X, 5 p.Article

Acute Profound Thrombocytopenia Associated with Readministration of Eptifibatide: Case Report and Review of the LiteratureRUSSELL, Kimberly N; SCHNABEL, Joseph G; ROCHETTO, Richard P et al.Pharmacotherapy. 2009, Vol 29, Num 7, pp 867-874, issn 0277-0008, 8 p.Article

Prehospital therapy with the platelet glycoprotein IIb/IIIa inhibitor eptifibatide in patients with suspected acute coronary syndromes: The Bochum feasibility studyHANEFELD, Christoph; SIRTL, Clemens; SPIECKER, Martin et al.Chest. 2004, Vol 126, Num 3, pp 935-941, issn 0012-3692, 7 p.Article

Cost-effectiveness analysis of antithrombotic therapy in nonurgent percutaneous coronary interventionSUMMERS, Kelly M; HOLDFORD, David A; CROUCH, Michael A et al.Pharmacotherapy. 2006, Vol 26, Num 5, pp 609-618, issn 0277-0008, 10 p.Article

From guidelines to clinical practice: the impact of hospital and geographical characteristics on temporal trends in the management of acute coronary syndromes: The Global Registry of Acute Coronary Events (GRACE)FOX, Keith A. A; GOODMAN, Shaun G; ANDERSON, Frederick A et al.European heart journal. 2003, Vol 24, Num 15, pp 1414-1424, issn 0195-668X, 11 p.Article

Efficacy and safety of early versus late glycoprotein IIb/IIIa inhibitors for PCIQIANG XU; JIAN YIN; SI, Liang-Yi et al.International journal of cardiology. 2013, Vol 162, Num 3, pp 210-219, issn 0167-5273, 10 p.Article

Randomized comparison between tirofiban and abciximab to promote complete ST-resolution in primary angioplasty : results of the facilitated angioplasty with tirofiban or abciximab (FATA) in ST-elevation myocardial infarction trialMARZOCCHI, Antonio; MANARI, Antonio; BINETTI, Nicola et al.European heart journal. 2008, Vol 29, Num 24, pp 2972-2980, issn 0195-668X, 9 p.Article

Bivalirudin Versus Heparin Plus a Glycoprotein IIb/IIIa Inhibitor in Patients With Non―ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention After Clopidogrel Pretreatment Pooled Analysis from the ACUITY and ISAR-REACT 4 TrialsNDREPEPA, Gjin; NEUMANN, Franz-Josef; DELIARGYRIS, Efthymios N et al.Circulation. Cardiovascular interventions. 2012, Vol 5, Num 5, pp 705-712, issn 1941-7640, 8 p.Article

Use and efficacy of abciximab in an unselected population with acute myocardial infarction treated with primary angioplasty : Data from AMI-Florence registrySANTORO, G. M; CARRABBA, N; BARCHIELLI, A et al.Atherosclerosis. 2007, Vol 195, Num 1, pp 116-121, issn 0021-9150, 6 p.Article

Beneficial effects of intracoronary tirofiban bolus administration following upstream intravenous treatment in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: The ICT-AMI studyTIAN QI ZHU; QI ZHANG; WEI FENG SHEN et al.International journal of cardiology. 2013, Vol 165, Num 3, pp 437-443, issn 0167-5273, 7 p.Article

Balancing safety and efficacy: recent clinical evidence optimizing outcomes in patients with intermediate to high-risk non-ST-segment elevated acute coronary syndromeVALGIMIGLI, Marco.European heart journal supplements. 2010, Vol 12, Num D, issn 1520-765X, D14-D23Article

Intracoronary application of abciximab in patients with ST-elevation myocardial infarctionWÖHRLE, Jochen; NUSSER, Thorsten; MAYER, Christine et al.EuroIntervention. 2008, Vol 3, Num 4, pp 465-469, issn 1774-024X, 5 p.Article